President and Founder
Amylyx Pharmaceuticals Inc
United States of America
Justin Klee co-founded Amylyx Pharmaceuticals in 2013 with Joshua Cohen. Justin has leveraged his extensive experience in neurophysiology and Alzheimer’s Disease research to help build and evaluate Amylyx’s novel platform and therapeutic for neurodegenerative diseases. Justin’s research includes work at Brown University and Harvard Medical School. He received his Sc.B in Neuroscience from Brown University.
mylyx is developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that targets the neuroinflammation and nerve cell death that characterize these disorders. The company’s therapeutic, AMX0035, is a proprietary combination of existing compounds that Amylyx has demonstrated have synergistic effects in preventing nerve cell death and neurotoxic inflammation in multiple preclinical models.